Cellectar Biosciences Inc.(CLRB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CLRB Cellectar Biosciences Inc.

已收盘 10-29 16:00:00 EDT

1.22

-0.02

-1.61%

盘后1.19

-0.03-2.46%

19:48 EDT

最高1.26	最低1.19	成交量11.19万
今开1.22	昨收1.24	日振幅5.65%
总市值1,153万	流通市值1,099万	总股本945.21万
成交额13.71万	换手率1.24%	流通股本900.82万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CLRB","market":"US","secType":"STK","nameCN":"Cellectar Biosciences Inc.","latestPrice":1.22,"timestamp":1793304000000,"preClose":1.24,"halted":0,"volume":111908,"hourTrading":{"tag":"盘后","latestPrice":1.19,"preClose":1.22,"latestTime":"19:48 EDT","volume":658,"amount":787.2529,"timestamp":1793317716690,"change":-0.03,"changeRate":-0.02459,"amplitude":0.02459},"delay":0,"changeRate":-0.01612903225806453,"floatShares":9008238,"shares":9452100,"eps":-2.21,"marketStatus":"已收盘","change":-0.02,"latestTime":"10-29 16:00:00 EDT","open":1.22,"high":1.26,"low":1.19,"amount":137060.7666132,"amplitude":0.056452,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.21,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793347200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.24,"preHourTrading":{"tag":"盘前","latestPrice":1.21,"preClose":1.24,"latestTime":"09:05 EDT","volume":69,"amount":83.49,"timestamp":1793279106117,"change":-0.03,"changeRate":-0.024194,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.19,"preClose":1.22,"latestTime":"19:48 EDT","volume":658,"amount":787.2529,"timestamp":1793317716690,"change":-0.03,"changeRate":-0.02459,"amplitude":0.02459},"volumeRatio":1.052277,"impliedVol":1.1856,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/CLRB","defaultTab":"news","newsList":[{"id":"1162256047","title":"Stempoint Capital Lp 披露对Cellectar Biosciences持有9.9%被动股权，截至6月30日","url":"https://stock-news.laohu8.com/highlight/detail?id=1162256047","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162256047?lang=zh_cn&edition=full","pubTime":"2026-08-15 00:04","pubTimestamp":1786723459,"startTime":"0","endTime":"0","summary":"Stempoint Capital Lp 在最新提交的SEC文件中披露，截至6月30日，该公司持有Cellectar Biosciences Inc.（股票代码：CLRB）9.9%的被动股权。这一持股比例以被动身份持有，表明该基金无主动影响公司运营或战略的意图。该文件于近日公开，反映了Stempoint Capital在生物科技领域的投资布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151739599","title":"Cellectar Biosciences 启动 Iopfosine I 131 三期临床研究站点激活，计划于2027年中提交新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1151739599","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151739599?lang=zh_cn&edition=full","pubTime":"2026-08-13 19:18","pubTimestamp":1786619889,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences 已正式启动其 Iopfosine I 131 三期临床研究的站点激活工作。这家生物科技公司同时透露，计划在2027年中期向监管机构提交新药申请（NDA）。这一进展标志着该候选药物在研发道路上迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112433397","title":"Cellectar Biosciences Inc. 提交文件，拟由售股股东发行至多5120万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1112433397","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112433397?lang=zh_cn&edition=full","pubTime":"2026-05-20 05:09","pubTimestamp":1779224951,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences Inc. 已向美国证券交易委员会提交相关文件，计划由售股股东发行至多5120万股普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121673150","title":"Cellectar Biosciences公布2B期Clover Wam研究12个月随访数据 Iopofosine I 131在R/R华氏巨球蛋白血症中展现持久疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1121673150","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121673150?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:13","pubTimestamp":1777979585,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences公司最新发布的2B期Clover Wam研究12个月随访数据证实，其核心候选药物Iopofosine I 131在治疗复发/难治性华氏巨球蛋白血症（R/R WM）领域展现出持久的治疗反应与显著的临床疗效。\n长期随访结果进一步验证了该放射性药物治疗方案的潜力，为这类罕见血液恶性肿瘤患者提供了新的希望。数据显示，接受治疗的患者在12个月观察期内持续产生深度缓解，药物安全性特征与早期研究结果保持一致。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121969203","title":"Cellectar Biosciences 推进在BTK抑制剂治疗后一线患者中启动验证性随机研究计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1121969203","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121969203?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:12","pubTimestamp":1777979576,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences Inc. (CLRB) 正积极推进其临床开发战略，计划在一线治疗失败且已接受过BTK抑制剂治疗的患者群体中，启动一项关键的验证性随机研究。这项研究旨在进一步评估其核心疗法的有效性与安全性，为该药物在更广泛临床场景中的应用提供坚实证据。\n公司此举标志着其研发管线的重要进展，目标是为现有治疗方案有限的难治性患者群体探索新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108350779","title":"Cellectar Biosciences公布二期CLOVER WAM试验结果：客观缓解率达83.6%，主要缓解率61.8%，中位缓解持续时间17.8个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1108350779","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108350779?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:11","pubTimestamp":1777979506,"startTime":"0","endTime":"0","summary":"在备受瞩目的二期CLOVER WAM临床试验中，Cellectar Biosciences Inc.交出了一份亮眼的成绩单。数据显示，该试验取得了83.6%的客观缓解率（ORR）和61.8%的主要缓解率（MRR），尤为突出的是，患者的中位缓解持续时间达到了17.8个月。\n这一系列积极数据显著超越了既定目标，为该公司在研疗法的有效性和持久性提供了强有力的证据。长久的缓解持续时间，尤其预示着该疗法可能为患者带来更具实质性的临床获益。\n试验结果的公布，无疑为Cellectar Biosciences的未来发展注入了强劲动力，也使其在竞争激烈的生物技术领域占据了更为有利的位置。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156897620","title":"Cellectar Biosciences Inc. 完成新一轮融资，由Nantahala Capital领投，多家知名医疗投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=1156897620","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156897620?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:10","pubTimestamp":1777979451,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences Inc. (CLRB) 成功完成一轮融资，本轮融资由Nantahala Capital Management, LLC 领投。值得注意的是，数家大型医疗健康领域的专业投资机构也参与了此次投资，显示出市场对Cellectar Biosciences Inc. 发展前景的强烈信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518224030","title":"Cellectar Biosciences, Inc.盘中异动 大幅上涨5.79%报0.336美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518224030","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518224030?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:38","pubTimestamp":1741613933,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时38分，Cellectar Biosciences, Inc.股票出现异动，股价大幅上涨5.79%。截至发稿，该股报0.336美元/股，成交量29.5357万股，换手率0.64%，振幅5.53%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.41%。其相关个股中，Trevi Therapeutics, Inc.、Checkpoint Therapeutics, Inc.、Scisparc Ltd.涨幅较大，Scisparc Ltd.、Dogwood Therapeutics, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为482.63%、74.60%、55.47%，振幅较大的相关个股有Seer, Inc.、Scisparc Ltd.、Impact Biomedical, Inc.，振幅分别为98.72%、34.57%、25.80%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021385398a29e82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021385398a29e82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517167845","title":"Cellectar Biosciences, Inc.盘中异动 早盘股价大涨5.37%报0.320美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517167845","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517167845?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:09","pubTimestamp":1741277382,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日00时09分，Cellectar Biosciences, Inc.股票出现异动，股价大幅上涨5.37%。截至发稿，该股报0.320美元/股，成交量22.5693万股，换手率0.49%，振幅7.28%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.29%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000942a262a80a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000942a262a80a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517677945","title":"Cellectar Biosciences, Inc.盘中异动 早盘大幅上涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517677945","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517677945?lang=zh_cn&edition=full","pubTime":"2025-03-05 23:00","pubTimestamp":1741186827,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日23时00分，Cellectar Biosciences, Inc.股票出现波动，股价快速拉升5.26%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为1.27%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Nutriband Inc C/Wts 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为722.68%、276.27%、237.00%，振幅较大的相关个股有Nkgen Biotech, Inc.、180 Life Sciences Corp C/Wts 07/11/2025、Silexion Therapeutics Corp，振幅分别为40.77%、36.89%、33.33%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305230027abe9ba43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305230027abe9ba43&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516637894","title":"Cellectar Biosciences, Inc.盘中异动 早盘股价大涨5.08%报0.304美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516637894","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516637894?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:47","pubTimestamp":1741013272,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时47分，Cellectar Biosciences, Inc.股票出现异动，股价快速拉升5.08%。截至发稿，该股报0.304美元/股，成交量10.2894万股，换手率0.22%，振幅2.73%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.05%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Geovax Labs, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为346.65%、109.40%、66.34%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Geovax Labs Inc C/Wts 29/09/2025，振幅分别为140.46%、68.30%、24.83%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032247529637b100&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032247529637b100&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514850662","title":"Cellectar Biosciences, Inc.盘中异动 大幅拉升5.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514850662","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514850662?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:40","pubTimestamp":1740588037,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日00时40分，Cellectar Biosciences, Inc.股票出现波动，股价快速上涨5.57%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。其相关个股中，Enveric Biosciences, Inc.、Pds Biotechnology Corporation、Renovaro Inc.涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为5929.07%、215.68%、215.55%，振幅较大的相关个股有Enveric Biosciences, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Organovo Holdings, Inc.，振幅分别为181.36%、49.18%、43.31%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270040379893c314&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502270040379893c314&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514905560","title":"Cellectar Biosciences, Inc.盘中异动 股价大涨5.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514905560","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514905560?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:31","pubTimestamp":1740493879,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时31分，Cellectar Biosciences, Inc.股票出现异动，股价大幅上涨5.46%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。其相关个股中，Organovo Holdings, Inc.、Moleculin Biotech, Inc.、Silexion Therapeutics Corp涨幅较大，Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为748.35%、529.64%、461.94%，振幅较大的相关个股有Organovo Holdings, Inc.、Adial Pharmaceuticals, Inc、Maze Therapeutics, Inc.，振幅分别为43.36%、19.20%、8.87%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022522312098924c5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022522312098924c5f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514705674","title":"Cellectar Biosciences, Inc.盘中异动 临近收盘股价大跌5.56%报0.294美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514705674","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514705674?lang=zh_cn&edition=full","pubTime":"2025-02-25 04:57","pubTimestamp":1740430678,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日04时57分，Cellectar Biosciences, Inc.股票出现异动，股价急速下跌5.56%。截至发稿，该股报0.294美元/股，成交量65.8749万股，换手率1.43%，振幅4.98%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.40%。其相关个股中，Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 涨幅较大，Pepgen Inc.、Aditxt, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为333.01%、145.74%、41.82%，振幅较大的相关个股有Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 ，振幅分别为176.22%、164.23%、81.92%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225045759a2526493&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225045759a2526493&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513347219","title":"Cellectar Biosciences, Inc.盘中异动 下午盘股价大跌5.53%报0.316美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513347219","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513347219?lang=zh_cn&edition=full","pubTime":"2025-02-22 03:04","pubTimestamp":1740164660,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日03时04分，Cellectar Biosciences, Inc.股票出现波动，股价快速下跌5.53%。截至发稿，该股报0.316美元/股，成交量50.4275万股，换手率1.09%，振幅7.75%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Revolution Medicines Inc C/Wts 17/12/2026 、Invivyd, Inc.涨幅较大，Aditxt, Inc.、Nkgen Biotech, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为298.79%、247.85%、136.62%，振幅较大的相关个股有Osr Holdings, Inc.、Invivyd, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为76.52%、70.25%、61.26%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222030420a24ee874&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222030420a24ee874&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512416530","title":"Cellectar Biosciences, Inc.盘中异动 早盘大幅拉升7.50%报0.313美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512416530","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512416530?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:32","pubTimestamp":1739889131,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时32分，Cellectar Biosciences, Inc.股票出现异动，股价快速上涨7.50%。截至发稿，该股报0.313美元/股，成交量9.5016万股，换手率0.21%，振幅0.00%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.11%。其相关个股中，Solid Biosciences Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Glycomimetics, Inc.涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为276.23%、91.16%、60.68%，振幅较大的相关个股有Allogene Therapeutics, Inc.、Cns Pharmaceuticals, Inc.、Allakos Inc.，振幅分别为9.56%、8.57%、8.35%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223211a24aacc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223211a24aacc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511611737","title":"Cellectar Biosciences, Inc.盘中异动 股价大涨5.91%报0.298美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511611737","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511611737?lang=zh_cn&edition=full","pubTime":"2025-02-15 03:34","pubTimestamp":1739561694,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日03时34分，Cellectar Biosciences, Inc.股票出现波动，股价急速拉升5.91%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.62%。其相关个股中，Moleculin Biotech, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Allogene Therapeutics, Inc.涨幅较大，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为3108.86%、792.24%、617.89%，振幅较大的相关个股有Lexaria Bioscience Corp C/Wts 14/01/2026 、Moleculin Biotech, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为74.35%、71.65%、66.45%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215033454abcf45fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215033454abcf45fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511525178","title":"Cellectar Biosciences, Inc.盘中异动 早盘股价大跌9.53%报0.260美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511525178","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511525178?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:37","pubTimestamp":1739457466,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时37分，Cellectar Biosciences, Inc.股票出现异动，股价大幅下挫9.53%。截至发稿，该股报0.260美元/股，成交量13.1259万股，换手率0.28%，振幅5.18%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.13%。其相关个股中，Edesa Biotech, Inc.、Dominari Holdings Inc.、Pliant Therapeutics, Inc.涨幅较大，Tc Biopharm  Plc、Edesa Biotech, Inc.、Genprex, Inc.较为活跃，换手率分别为1008.65%、888.51%、98.43%，振幅较大的相关个股有Ocean Biomedical Inc C/Wts 14/02/2028 、Edesa Biotech, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 ，振幅分别为32.86%、25.80%、19.13%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021322374798842cf7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021322374798842cf7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510886380","title":"Cellectar Biosciences, Inc.盘中异动 大幅下挫5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510886380","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510886380?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:35","pubTimestamp":1739284551,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时35分，Cellectar Biosciences, Inc.股票出现异动，股价快速跳水5.23%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.83%。其相关个股中，Dominari Holdings Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 、Lipella Pharmaceuticals Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、In8Bio, Inc.较为活跃，换手率分别为2084.07%、546.69%、182.24%，振幅较大的相关个股有In8Bio, Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.，振幅分别为25.06%、22.23%、18.18%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112235529881bdc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112235529881bdc7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLRB","OCEA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510634718","title":"Cellectar Biosciences, Inc.股价上涨10.04% 市值涨128.09万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510634718","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510634718?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:31","pubTimestamp":1739197867,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时31分，Cellectar Biosciences, Inc.股票出现异动，股价急速上涨10.04%。截至发稿，该股报0.330美元/股，成交量50.1161万股，换手率1.09%，振幅0.00%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.38%。其相关个股中，Biodexa Pharmaceuticals Plc、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Ocean Biomedical, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃，换手率分别为1449.95%、834.07%、547.77%，振幅较大的相关个股有Aditxt, Inc.、Tc Biopharm  Plc、Kazia Therapeutics Limited，振幅分别为6.44%、5.96%、4.90%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223107a240a1ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223107a240a1ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cellectar.com","stockEarnings":[{"period":"1week","weight":-0.0313},{"period":"1month","weight":-0.3224},{"period":"3month","weight":-0.5099},{"period":"6month","weight":-0.539},{"period":"1year","weight":-0.6254},{"period":"ytd","weight":-0.5797}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0088},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.0717},{"period":"1year","weight":0.1241},{"period":"ytd","weight":0.1326}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cellectar Biosciences, Inc.以前名为Novelos Therapeutics, Inc.于1996年6月成立于特拉华州。2014年2月11日，公司更名为现在的名字。该公司是一家后期临床生物制药公司，专注于癌症治疗药物的发现、开发和商业化。该公司的核心目标是利用专有的磷脂醚药物偶联物递送平台开发PDC，这些PDC旨在专门针对癌细胞，并由于更少的脱靶效应而提供更好的功效和更好的安全性。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.017624},{"month":2,"riseRate":0.666667,"avgChangeRate":0.024048},{"month":3,"riseRate":0.5,"avgChangeRate":-0.034403},{"month":4,"riseRate":0.25,"avgChangeRate":-0.094306},{"month":5,"riseRate":0.416667,"avgChangeRate":0.057843},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.0753},{"month":7,"riseRate":0.25,"avgChangeRate":-0.094568},{"month":8,"riseRate":0.416667,"avgChangeRate":-0.014253},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.043384},{"month":10,"riseRate":0.076923,"avgChangeRate":-0.172553},{"month":11,"riseRate":0.416667,"avgChangeRate":-0.062866},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.062943}],"exchange":"NASDAQ","name":"Cellectar Biosciences Inc.","nameEN":"Cellectar Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cellectar Biosciences Inc.(CLRB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cellectar Biosciences Inc.(CLRB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cellectar Biosciences Inc.,CLRB,Cellectar Biosciences Inc.股票,Cellectar Biosciences Inc.股票老虎,Cellectar Biosciences Inc.股票老虎国际,Cellectar Biosciences Inc.行情,Cellectar Biosciences Inc.股票行情,Cellectar Biosciences Inc.股价,Cellectar Biosciences Inc.股市,Cellectar Biosciences Inc.股票价格,Cellectar Biosciences Inc.股票交易,Cellectar Biosciences Inc.股票购买,Cellectar Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cellectar Biosciences Inc.(CLRB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cellectar Biosciences Inc.(CLRB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}